In JO25567 and NEJ026 studies, combination therapy with bevacizumab and erlotinib improves PFS, compared with using erlotinib alone, in patients with EGFR‐positive NSCLC, especially for those having pleural/pericardial effusion.19, 20. This evidence concerns the gene EGFR and non-small cell lung carcinoma.